Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ‑based proteomics

Wang,Yuanjing; Li,Hongxia

doi:10.3892/ol.2018.8600

Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ‑based proteomics

Authors:
- Yuanjing Wang
- Hongxia Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China
Published online on: April 27, 2018 https://doi.org/10.3892/ol.2018.8600
Pages: 9793-9801
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is an important adjuvant therapy for epithelial ovarian cancer (EOC). The main cause of chemotherapy failure in EOC is paclitaxel resistance. The present study aimed to identify novel biomarkers to predict chemosensitivity to paclitaxel and improve our understanding of the molecular mechanisms underlying paclitaxel resistance in EOC. In the present study, the heterogeneity of EOC was evaluated by adenosine triphosphate‑tumor chemosensitivity assay (ATP‑TCA) in vitro. Fresh samples were collected from 54 EOC cases during cytoreductive surgery. Tumor cells were isolated, cultured, and tested for sensitivity to paclitaxel. Proteins that were differentially expressed between paclitaxel‑resistant tissues and paclitaxel‑sensitive tissues were identified via isobaric tags for relative and absolute quantitation (iTRAQ)‑based proteomic analysis. Two upregulated proteins, plexin domain containing 2 (Plxdc2) and cytokeratin 7 (CK7), were selected to verify the iTRAQ method using western blot analysis in EOC tissues with different chemosensitivities (sensitive, weakly sensitive and resistant). There was notable heterogeneity of chemosensitivity in the EOC specimens. Highly to mildly‑differentiated or early‑stage (I/II) EOC specimens had decreased sensitivity to paclitaxel compared with specimens with low differentiation (P<0.05) or an advanced stage (III; P<0.05), respectively. A total of 496 significantly differentially expressed proteins, including 263 that were downregulated (P<0.05) and 233 that were upregulated (P<0.05) in paclitaxel‑resistant tissues compared with paclitaxel‑sensitive tissues, were identified using iTRAQ in combination with LC‑MS/MS. The expression levels of two proteins associated with paclitaxel resistance, Plxdc2 and CK7, were further validated by western blotting, which revealed that they were upregulated in the paclitaxel‑resistant tissues. The present study determined candidate proteins associated with paclitaxel resistance in EOC. Plxdc2 and CK7 may be potential makers for distinguishing patients with paclitaxel‑resistant EOC from those with paclitaxel‑sensitive EOC.

View Figures

View References

1	Cornelison R, Llaneza DC and Landen CN: Emerging Therapeutics to overcome chemoresistance in epithelial ovarian cancer: A mini-review. Int J Mol Sci. 18:E21712017. View Article : Google Scholar : PubMed/NCBI
2	Duda K, Cholewa H, Łabuzek K, Boratyn-Nowicka A and Okopień B: Novel strategies of ovarian cancer treatment. Pol Merku Lekarski. 39:337–342. 2015.
3	Ramalingam P: Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 30:166–176. 2016.PubMed/NCBI
4	Bookman MA: Optimal primary therapy of ovarian cancer. Ann Oncol. 27 Suppl 1:i158–i162. 2016. View Article : Google Scholar
5	Matsumoto K, Onda T and Yaegashi N: Pharmacotherapy for recurrent ovarian cancer: Current status and future perspectives. Jpn J Clin Oncol. 45:408–410. 2015. View Article : Google Scholar : PubMed/NCBI
6	O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ and Curtin NJ: Advanced ovarian cancerdisplays functional intratumor heterogeneity that correlates to ex vivo drug sensitivity. Int J Gynecol Cancer. 26:1004–1011. 2016. View Article : Google Scholar : PubMed/NCBI
7	Tatar B, Boyraz G, Selçuk İ, Doğan AK, Usubütün A and Tuncer ZS: In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays. J Turk Ger Gynecol Assoc. 17:35–40. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhang H, Zhang L, Wei L, Gao X, Tang LI, Gong W, Min NA, Zhang LI and Yuan Y: Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapy. Oncol Lett. 11:4235–4239. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT and Kim S: ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. Yonsei Med J. 55:1664–1671. 2014. View Article : Google Scholar : PubMed/NCBI
10	Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP and Kang SB: Predictive value of individualized tumor response testing by ATP based chemotherapy response assay in ovarian cancer. Cancer Invest. 26:426–430. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zhao D, Zhang W, Li XG, Wang XB, Zhang LF, Li M, Li YF, Tian HM, Song PP, Liu J, et al: Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemo-sensitivity assay combined with detection of drug resistance genes. Zhonghua Fu Chan Ke Za Zhi. 46:193–198. 2011.(In Chinese). PubMed/NCBI
12	Fehm T, Zwirner M, Wallwiener D, Seeger H and Neubauer H: Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer. 12:3082012. View Article : Google Scholar : PubMed/NCBI
13	Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D and Fehm T: Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 28:949–955. 2008.PubMed/NCBI
14	Safinya CR, Chung PJ, Song C, Li Y, Ewert KK and Choi MC: The effect of multivalent cations and Tau on paclitaxel-stabilized microtubule assembly, disassembly, and structure. Adv Colloid Interface Sci. 232:9–16. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tian Y, Tan AC, Sun X, Olson MT, Xie Z, Jinawath N, Chan DW, Shih IeM, Zhang Z and Zhang H: Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance. Proteomics Clin Appl. 3:1288–1295. 2009. View Article : Google Scholar : PubMed/NCBI
16	Gagné JP, Ethier C, Gagné P, Mercier G, Bonicalzi ME, Mes-Masson AM, Droit A, Winstall E, Isabelle M and Poirier GG: Comparative proteome analysis of human epithelial ovarian cancer. Proteome Sci. 5:162007. View Article : Google Scholar : PubMed/NCBI
17	Tian Y, Yao Z, Roden RB and Zhang H: Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics. 11:4677–4687. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ling ZQ, Qi CJ, Lu XX, Qian LJ, Gu LH, Zheng ZG, Zhao Q, Wang S, Fang XH, Yang ZX, et al: Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 33:401–406. 2012. View Article : Google Scholar : PubMed/NCBI
19	Konecny G, Crohns C, Pelgram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H and Untch M: Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol. 77:258–263. 2000. View Article : Google Scholar : PubMed/NCBI
20	Wang H, Wu K, Liu Y, Wu Y and Wang X: Integrative proteomics to understand the transmission mechanism of Barley yellow dwarf virus-GPV by its insect vector Rhopalosiphum padi. Sci Rep. 5:109712015. View Article : Google Scholar : PubMed/NCBI
21	Perkins DN, Pappin DJ, Creasy DM and Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 20:3551–3567. 1999. View Article : Google Scholar : PubMed/NCBI
22	Zhong XW, Zou Y, Liu SP, Yi QY, Hu CM, Wang C, Xia QY and Zhao P: Proteomic-based insight into Malpighian tubules of silkworm Bombyx mori. PLoS One. 8:e757312013. View Article : Google Scholar : PubMed/NCBI
23	Shan N, Zhou W, Zhang S and Zhang Y: Identification of HSPA8 as a candidate biomarker for endometrial carcinoma by using iTRAQ-based proteomic analysis. Onco Targets Ther. 9:2169–2179. 2016.PubMed/NCBI
24	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
25	The Gene Ontology Consortium: Expansion of the Gene Ontology knowledgebase and resources. Nucleic Acids Res. 45:D331–D338. 2017. View Article : Google Scholar : PubMed/NCBI
26	Christie M and Oehler MK: Molecular pathology of epithelial ovarian cancer. J Br Menopause Soc. 12:57–63. 2006. View Article : Google Scholar : PubMed/NCBI
27	Giordano S, Zucchetti M, Decio A, Cesca M, Nerini Fuso I, Maiezza M, Ferrari M, Licandro SA, Frapolli R, Giavazzi R, et al: Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Sci Rep. 6:392842016. View Article : Google Scholar : PubMed/NCBI
28	Symeonides S and Gourley C: Ovarian cancer molecular stratification and tumor heterogeneity: A necessity and a challenge. Front Oncol. 5:2292015. View Article : Google Scholar : PubMed/NCBI
29	Zhang J and Li H: Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using theadenosine triphosphate-tumor chemosensitivity assay. Oncol Lett. 9:2374–2380. 2015. View Article : Google Scholar : PubMed/NCBI
30	Miller-Delaney SF, Lieberam I, Murphy P and Mitchell KJ: Plxdc2 is a mitogen for neural progenitors. PLoS One. 6:e145652011. View Article : Google Scholar : PubMed/NCBI
31	Miller SF, Summerhurst K, Rünker AE, Kerjan G, Friedel RH, Chédotal A, Murphy P and Mitchell KJ: Expression of Plxdc2/TEM7R in the developing nervous system of the mouse. Gene Expr Patterns. 7:635–644. 2007. View Article : Google Scholar : PubMed/NCBI
32	Qi W, Yang C, Dai Z, Che D, Feng J, Mao Y, Cheng R, Wang Z, He X, Zhou T, et al: High levels of pigment epithelium-derived factor in diabetes impair wound healing through suppression of Wnt signaling. Diabetes. 64:1407–1419. 2015. View Article : Google Scholar : PubMed/NCBI
33	Cheng G, Zhong M, Kawaguchi R, Kassai M, Al-Ubaidi M, Deng J, Ter-Stepanian M and Sun H: Identification of PLXDC1 and PLXDC2 as the transmembrane receptors for the multifunctional factor PEDF. Elife. 3:e054012014. View Article : Google Scholar : PubMed/NCBI
34	Sagheer U, Gong J and Chung C: Pigment Epithelium-Derived Factor (PEDF) is a determinant of stem cell fate: Lessons from an Ultra-Rare disease. J Dev Biol. 3:112–128. 2015. View Article : Google Scholar : PubMed/NCBI
35	Zhang S, Zhai G, Shi W, Wang Y, Zhu L, Dai Y and Chen C: Pigment Epithelium-Derived factor inhibits oxygen-induced retinal neovascularization in a murine model. Fetal Pediatr Pathol. 35:173–185. 2016. View Article : Google Scholar : PubMed/NCBI
36	Belkacemi L and Zhang SX: Anti-tumor effects of Pigment Epithelium-Derived Factor (PEDF): Implication for cancer therapy. A mini-review. J Exp Clin Cancer Res. 35:42016. View Article : Google Scholar : PubMed/NCBI
37	Chuderland D, Ben-Ami I, Bar-Joseph H and Shalgi R: Role of pigment epithelium-derived factor in the reproductive system. Reproduction. 148:R53–R61. 2014. View Article : Google Scholar : PubMed/NCBI
38	Sandilands A, Smith FJ, Lunny DP, Campbell LE, Davidson KM, MacCallum SF, Corden LD, Christie L, Fleming S, Lane EB and McLean WH: Generation and characterisation of Keratin 7 (K7) knockout mice. PLoS One. e644042013. View Article : Google Scholar : PubMed/NCBI
39	Windoffer R, Beil M, Magin TM and Leube RE: Cytoskeleton in motion: The dynamics of keratin intermediate filaments in epithelia. J Cell Biol. 194:669–678. 2011. View Article : Google Scholar : PubMed/NCBI
40	Bayrak R, Yenidunya S and Haltes H: Cytokeratin 7 and Cytokeratin 20 expression in colorectal adenocarcinoma. Pathol Res Pract. 207:156–160. 2011. View Article : Google Scholar : PubMed/NCBI
41	Gurzu S and Jung I: Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutation. Pathol Res Pract. 208:163–166. 2012. View Article : Google Scholar : PubMed/NCBI
42	Toyoshima M, Momono Y, Makino H, Kudo T, Oka N, Sakurada J, Suzuki H, Kodama H and Yoshinaga K: Cytokeratin 7-positive/cytokeratin 20-negative cecal adenocarcinoma metastaticto the uterine cervix: A case report. World J Surg Oncol. 14:222016. View Article : Google Scholar : PubMed/NCBI
43	Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
44	Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS and Lee KY: CK7, CK20, CDX2 and MUC2 Immunohisto-chemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 40:208–213. 2010. View Article : Google Scholar : PubMed/NCBI
45	Moll R, Divo M and Langbein L: The human keratins: Biology and pathology. Histochem Cell Biol. 129:705–733. 2008. View Article : Google Scholar : PubMed/NCBI